Evidence map›Paper›PMID 40650228›Full record

ArticleInternational journal of molecular sciences2025

Nodal Expansion, Tumor Infiltration and Exhaustion of Neoepitope-Specific Th Cells After Prophylactic Peptide Vaccination and Anti-CTLA4 Therapy in Mouse Melanoma B16.

Alexandra V Shabalkina, Anna V Izosimova, Ekaterina O Ryzhichenko, Elizaveta V Shurganova, Daria S Myalik, Sofia V Maryanchik, Valeria K Ruppel, Dmitriy I Knyazev, Nadezhda R Khilal, Ekaterina V Barsova and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexandra V ShabalkinaResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.
Anna V IzosimovaResearch Institute of Experimental Oncology and Translational Biomedicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., Nizhny Novgorod 603950, Russia.
Ekaterina O RyzhichenkoDepartment of Genomics of Adaptive Immunity, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, 16/10 Miklukho-Maklaya, Moscow 117997, Russia.
Elizaveta V ShurganovaResearch Institute of Experimental Oncology and Translational Biomedicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., Nizhny Novgorod 603950, Russia.
Daria S MyalikResearch Institute of Experimental Oncology and Translational Biomedicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., Nizhny Novgorod 603950, Russia.
Sofia V MaryanchikResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.ORCID 0000-0003-1448-132X
Valeria K RuppelResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.
Dmitriy I KnyazevMolecular Genetics Laboratory, The University Clinic, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., Nizhny Novgorod 603950, Russia.
Nadezhda R KhilalMolecular Genetics Laboratory, The University Clinic, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., Nizhny Novgorod 603950, Russia.
Ekaterina V BarsovaResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.
Irina A ShaginaResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.
George V SharonovResearch Institute of Translational Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova, Moscow 117997, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide vaccines possess several advantages over mRNA vaccines but are generally less effective at inducing antitumor immunity. The bottlenecks limiting peptide vaccine efficacy could be elucidated by tracking and comparing vaccine-induced T-lymphocytes in successful and unsuccessful cases. Here we have applied our recent database of neoantigen-specific T cell receptors (TCRs) to profile tumor-specific T cells following vaccination with a neoantigen peptide vaccine and to correlate this with the response. Mice were vaccinated prophylactically with p30 peptide encoding B16 melanoma neoantigen (K739N mutation in

Indexed as

Cancer VaccinesCTLA-4 AntigenLymph NodesMelanoma, ExperimentalT-Lymphocytes, Helper-InducerVaccines, SubunitAnimalsAntigens, NeoplasmCell Line, TumorFemaleLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLReceptors, Antigen, T-CellVaccinationAntigens, NeoplasmCancer VaccinesCTLA-4 AntigenCtla4 protein, mouseReceptors, Antigen, T-CellVaccines, SubunitB16 melanomapeptide anticancer vaccineTCR repertoire

Identifiers

PMID40650228
PMCPMC12249801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.